Previous 10 | Next 10 |
home / stock / nvo / nvo articles
Denmark’s healthcare authority has decided to favor less expensive drugs for type 2 diabetes patients, impacting the prescription of costlier...
The Senate Committee on Health, Education, Labor, and Pensions is reportedly scrutinizing Novo Nordisk A/S (NYSE:NVO) ‘s pric...
A recent survey conducted by Morgan Stanley reveals that the use of GLP-1 drugs, popular for weight loss and diabetes, is affecting consu...
The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says t...
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 27.13% on an annualized basis producing an average annual return of 39...
U.S. District Judge Roy Altman ruled that the drugmaker Eli Lilly And Co (NYSE:LLY) cannot rely on state law to stop a compound...
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has determined that there is no substantial evid...
Ginkgo Bioworks Holdings, Inc. (NASDAQ:DNA) shares are volatile Thursday. The company announced the acquisition of AgBiome’s platform assets ...
After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company (NYSE:LLY) stock h...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...